| 6/11/2013 |
Modifications to be Cleared in Commercial Distribution |
Public Affairs |
Device Modification |
Comments |
| 6/10/2013 |
Docket No. FDA-2013-D-0168; Draft Guidance for Industry and Food and Drug Administration Staff; Recommendations for Labeling Medical Products to Inform Users that the Product or Product Container is not Made with Natural Rubber Latex |
Technology & Regulatory Affairs |
Latex |
Comments |
| 5/23/2013 |
AdvaMed EGCC Membership Benefits |
Public Affairs |
Membership Benefits |
Fact sheet |
| 5/14/2013 |
Docket No. FDA-2010-D-0194: Agency Information Collection Activities; Proposed Collection; Comment Request; Draft Guidance for Industry and FDA Staff; Total Product Life Cycle: Infusion PumpPremarket Notification [510(k)] Submissions; Notice |
Technology & Regulatory Affairs |
Infusion Pumps |
Comments |
| 4/25/2013 |
ENVI Committee Report |
Technology & Regulatory Affairs |
ENVI Committee |
Regulation |
| 4/25/2013 |
ENVI Committee Report IVDs |
Technology & Regulatory Affairs |
ENVI Report |
Regulation |
| 4/24/2013 |
Members of Congress Supporting H.R. 523 |
Government Affairs |
Device Tax |
Fact Sheet |
| 4/24/2013 |
Senate Committee On Finance: The Trans-Pacific Partnership |
Finance and Business Services |
Device Tax |
Testimony |
| 4/19/2013 |
Docket No. FDA
2009
N
0458; RIN 0910
AG29: Medical Devices; Pediatric Uses of Devices; Requirement for Submission of Information on Pediatric Subpopulations That Suffer From a Disease or Condition That a Device Is Intended To Treat, Diagnose, or Cure |
Technology & Regulatory Affairs |
Pediatric Subpopulations |
Comments |
| 4/19/2013 |
Docket No. FDA-2013-D-0117: Draft Guidance for Industry and Food and Drug Administration Staff; Providing Information About Pediatric Uses of Medical Devices Under Section 515A of the Federal Food, Drug, and Cosmetic Act; Availability |
Technology & Regulatory Affairs |
Pediatrics |
Comments |
| 4/12/2013 |
AdvaMed's Tax Reform Principles |
Public Affairs |
Tax Reform |
White Paper |
| 4/9/2013 |
AdvaMed Sunshine Comments on the Final Rule and Data Templates |
Legal |
Physician Payments Sunshine |
Comments |
| 3/29/2013 |
AdvaMed Comments on Implementation of the Medical Device Excise Tax Provisions of the Affordable Care Act – Comments on the Final Regulations and Notice 2012-77 |
Legal |
Device Tax |
Comments |
| 3/25/2013 |
The Neurointerventionalist and the AdvaMed Code of Ethics |
Legal |
Code of Ethics |
Guidance |
| 3/21/2013 |
Docket No. FDA
2010
D
0643: Draft Guidance for Industry on Electronic Source Data in Clinical Investigations; Correction |
Technology & Regulatory Affairs |
Clinical Investigations |
Comments |
| 3/18/2013 |
Docket No. FDA-2012-D-1145; Draft Guidance for Industry on Enrichment Strategies for Clinical Trials to Support Approval of Human Drugs and Biological Products |
Technology & Regulatory Affairs |
Enrichment Strategies |
Comments |
| 3/13/2013 |
Docket No. FDA
2012
D
1161: Draft Guidance for Industry and Food and Drug Administration Staff: Design Considerations for Devices Intended for Home Use; Availability |
Technology & Regulatory Affairs |
Home Use |
Comments |
| 3/5/2013 |
AdvaMed Code of Ethics Certification and Logo Supplement Package |
Legal |
Code Certification and Logo Package |
Fact sheet |
| 3/5/2013 |
AdvaMed Supports Continuing Resolution to Fund Government Operations |
Public Affairs |
Medical Devices |
Letter |
| 3/1/2013 |
AdvaMed, EucoMed, ABO: The Value of Harmonization Efforts in Blood Device Medical Technology |
Technology & Regulatory Affairs |
Device Harmonization |
White Paper |
| 3/1/2013 |
Morgan Lewis POD White Paper |
Legal |
Medical Device |
Comments |
| 3/1/2013 |
The Value of Harmonization Efforts in Blood Device Medical Technology |
Technology & Regulatory Affairs |
Blood Sector |
White Paper |
| 2/28/2013 |
International Board Committee Presentation: Emerging Markets |
Global |
Emerging Markets |
Presentation |
| 2/25/2013 |
Staff List by Department |
President's Office |
Staff List |
Administrative |
| 2/7/2013 |
Docket No. FDA-2012-D-1057; Draft Guidance for Industry and Food and Drug Administration Staff; Highly Multiplexed Microbiological/Medical Countermeasure in Vitro Nucleic Acid Based Diagnostic Devices |
Technology & Regulatory Affairs |
Highly Multiplexed Microbiological/Medical Countermeasure in IVDs |
Comments |